Initial characteristics of the 172 patients with primary myelofibrosis
| Characteristic . | Value . |
|---|---|
| Patients, no. | 172 |
| Age, y, median ± SD | 65 ± 9.69 |
| Hemoglobin, g/L, median ± SD | 104 ± 24.5 |
| White blood cell count, ×109/L, median ± SD | 11.25 ± 14.26 |
| Platelet count, ×109/L, median ± SD | 297 ± 276 |
| Abnormal cytogenetics* (%) | 30 of 89 (34) |
| Weight loss, n (%) | 33 (19) |
| Hepatomegaly, n (%) | 76 (44) |
| Male/female (ratio) | 90/82 (1.1:1) |
| Circulating blasts > 1%, n (%) | 60 (36) |
| Immature granulocytes > 5%, n (%) | 109 (64) |
| Treatment regimen, n (%) | |
| Chemotherapy | 84 (49) |
| Androgens | 33 (19) |
| Splenectomy | 28 (16) |
| Lille score, n (%) | |
| Low | 78 (45) |
| Intermediate | 77 (45) |
| High | 17 (10) |
| IWGMRT score,* n (%) | |
| Low | 18 (11) |
| Intermediate-low | 51 (31) |
| Intermediate-high | 56 (34) |
| High | 39 (24) |
| Characteristic . | Value . |
|---|---|
| Patients, no. | 172 |
| Age, y, median ± SD | 65 ± 9.69 |
| Hemoglobin, g/L, median ± SD | 104 ± 24.5 |
| White blood cell count, ×109/L, median ± SD | 11.25 ± 14.26 |
| Platelet count, ×109/L, median ± SD | 297 ± 276 |
| Abnormal cytogenetics* (%) | 30 of 89 (34) |
| Weight loss, n (%) | 33 (19) |
| Hepatomegaly, n (%) | 76 (44) |
| Male/female (ratio) | 90/82 (1.1:1) |
| Circulating blasts > 1%, n (%) | 60 (36) |
| Immature granulocytes > 5%, n (%) | 109 (64) |
| Treatment regimen, n (%) | |
| Chemotherapy | 84 (49) |
| Androgens | 33 (19) |
| Splenectomy | 28 (16) |
| Lille score, n (%) | |
| Low | 78 (45) |
| Intermediate | 77 (45) |
| High | 17 (10) |
| IWGMRT score,* n (%) | |
| Low | 18 (11) |
| Intermediate-low | 51 (31) |
| Intermediate-high | 56 (34) |
| High | 39 (24) |
SD indicates standard deviation.
Data were not available for all patients.